2. Academic Validation
  3. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain

  • Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. doi: 10.2217/nnm-2017-0190.
Andrew S Gdowski 1,  Amalendu Ranjan 1,  Marjana R Sarker 2,  Jamboor K Vishwanatha 1
Affiliations

Affiliations

  • 1 Institute for Molecular Medicine, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA.
  • 2 Center for Neuroscience Discovery, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA.
PMID: 28805551 DOI: 10.2217/nnm-2017-0190
Abstract

Aim: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment.

Materials & methods: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate Cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate Cancer was performed.

Results: This bone targeted cabazitaxel nanocarrier system showed significant reduction in tumor burden, while at the same time maintaining bone structure integrity and reducing pain in the mouse tumor limb.

Conclusion: This bone microenvironment targeted nanoparticle system and clinically relevant approach of evaluation represents a promising advancement for treating bone metastatic Cancer.

Keywords

bone metastasis; cabazitaxel; polymeric nanoparticle; prostate cancer; targeted therapeutic.

Figures
Products